â– LECTURE OVERVIEW: Diagnostic screening tests must be rigorously evaluated using conditional probability metrics to define their clinical utility.
â– SCREEN CHANNELS:
1. Sensitivity (True Positive Rate):
- Formula: Sensitivity = True Positives / (True Positives + False Negatives).
- Definition: The probability that the test is positive in a patient who truly has the disease.
- Mnemonics: 'SnNout'—a highly sensitive test has very few false negatives; thus, a negative result is powerful to rule OUT the disease.
2. Specificity (True Negative Rate):
- Formula: Specificity = True Negatives / (True Negatives + False Positives).
- Definition: The probability that the test is negative in a healthy patient who does not have the disease.
- Mnemonics: 'SpPIn'—a highly specific test has very few false positives; thus, a positive result is powerful to rule IN the disease.
â– PHARMACOKINETIC & PHARMACODYNAMIC ATTRIBUTES:
Absorption and steady-state kinetics display high variability based on plasma protein binding levels, tissue volume of distribution (Vd), and hepatic CYP450 microsomal enzymatic clearance indices.
â– HISTOCHEMICAL & SPECIAL STAIN ANALYSIS:
Tissue examination is enhanced by specialized dyes and immunophenotypic markers that target cellular structure with remarkable specificity.
[HY-BOARD-1332]
🌟 Dynamic Clinical Key:
In HIV diagnostics, a highly sensitive enzyme-linked immunosorbent assay (ELISA) is used first to screen blood supplies (ruling out false negatives). Any positive result is subsequently confirmed via western blot or viral load PCR, which are highly specific. Closely monitor serum plasma concentrations if drugs display a narrow therapeutic window to mitigate toxic peaks. Always cross-reference histochemical stains with structural boundaries on the biopsy.